Ultra High-Risk Multiple Myeloma Patients with Multi-Hit Tumours and SKY92 High Risk Signature Are at Increased Risk of Early Relapse Even When Treated with Extended Intensified Induction and Consolidation - Results from the Optimum/Muknine TrialMartin Kaiser, Matthew Jenner, Laura Clayton et al.|Blood|2023Cited by 8
Belantamab Mafodotin Plus Cyclophosphamide and Dexamethasone for Patients with Relapsed or Refractory Multiple Myeloma: Interim Results from the UK Myeloma Research Alliance Prommise Clinical TrialRakesh Popat, Christopher Parrish, Charlotte Pawlyn et al.|Blood|2024Cited by 3
Extended Intensified Consolidation and Maintenance Improve Ultra High-Risk Multiple Myeloma Patient Outcome - Long-Term Follow-up of the Ukmra Optimum/Muknine TrialMartin Kaiser, Matthew Jenner, Andrew Hall et al.|Blood|2024Cited by 2